Cargando…
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is repo...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070235/ https://www.ncbi.nlm.nih.gov/pubmed/27843623 http://dx.doi.org/10.1136/esmoopen-2016-000063 |
_version_ | 1782461103163310080 |
---|---|
author | Azuma, Koichi Hirashima, Tomonori Yamamoto, Nobuyuki Okamoto, Isamu Takahashi, Toshiaki Nishio, Makoto Hirata, Taizo Kubota, Kaoru Kasahara, Kazuo Hida, Toyoaki Yoshioka, Hiroshige Nakanishi, Kaoru Akinaga, Shiro Nishio, Kazuto Mitsudomi, Tetsuya Nakagawa, Kazuhiko |
author_facet | Azuma, Koichi Hirashima, Tomonori Yamamoto, Nobuyuki Okamoto, Isamu Takahashi, Toshiaki Nishio, Makoto Hirata, Taizo Kubota, Kaoru Kasahara, Kazuo Hida, Toyoaki Yoshioka, Hiroshige Nakanishi, Kaoru Akinaga, Shiro Nishio, Kazuto Mitsudomi, Tetsuya Nakagawa, Kazuhiko |
author_sort | Azuma, Koichi |
collection | PubMed |
description | BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is reported as a poor prognostic factor in various cancers. As c-Met is involved in EGFR-TKI resistance, a c-Met inhibitor and EGFR-TKI combination may reverse the resistance. This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. The primary end point was the overall response rate (ORR) and secondary end points included disease control rate, progression-free survival (PFS) and overall survival (OS). The patients underwent a mandatory second biopsy just after progression on EGFR-TKIs. The predictive biomarkers were extensively analysed using tumour and blood samples. RESULTS: The ORR was 6.7% (95% CI 1.4% to 18.3%), and the lower limit of 95% CI did not exceed the target of 5%. The median PFS (mPFS) and median OS (mOS) were 2.7 months (95% CI 1.4 to 4.2) and 18.0 months (95% CI 13.4 to 22.2), respectively. Both were longer in c-Met high patients (c-Met high vs low: mPFS 4.1 vs 1.4 months; mOS 20.7 vs 13.9 months). Partial response was observed in three patients, all of whom were c-Met and HGF high. The common adverse events and their frequencies were similar to those known to occur with tivantinib or erlotinib alone. CONCLUSIONS: Although this study did not prove clinical benefit of tivantinib in patients with acquired resistance to EGFR-TKIs, activated HGF/c-Met signalling, a poor prognostic factor, may define a patient subset associated with longer survival by the tivantinib/erlotinib combination. TRIAL REGISTRATION NUMBER: NCT01580735. |
format | Online Article Text |
id | pubmed-5070235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50702352016-11-14 Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib Azuma, Koichi Hirashima, Tomonori Yamamoto, Nobuyuki Okamoto, Isamu Takahashi, Toshiaki Nishio, Makoto Hirata, Taizo Kubota, Kaoru Kasahara, Kazuo Hida, Toyoaki Yoshioka, Hiroshige Nakanishi, Kaoru Akinaga, Shiro Nishio, Kazuto Mitsudomi, Tetsuya Nakagawa, Kazuhiko ESMO Open Original Research BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is reported as a poor prognostic factor in various cancers. As c-Met is involved in EGFR-TKI resistance, a c-Met inhibitor and EGFR-TKI combination may reverse the resistance. This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. The primary end point was the overall response rate (ORR) and secondary end points included disease control rate, progression-free survival (PFS) and overall survival (OS). The patients underwent a mandatory second biopsy just after progression on EGFR-TKIs. The predictive biomarkers were extensively analysed using tumour and blood samples. RESULTS: The ORR was 6.7% (95% CI 1.4% to 18.3%), and the lower limit of 95% CI did not exceed the target of 5%. The median PFS (mPFS) and median OS (mOS) were 2.7 months (95% CI 1.4 to 4.2) and 18.0 months (95% CI 13.4 to 22.2), respectively. Both were longer in c-Met high patients (c-Met high vs low: mPFS 4.1 vs 1.4 months; mOS 20.7 vs 13.9 months). Partial response was observed in three patients, all of whom were c-Met and HGF high. The common adverse events and their frequencies were similar to those known to occur with tivantinib or erlotinib alone. CONCLUSIONS: Although this study did not prove clinical benefit of tivantinib in patients with acquired resistance to EGFR-TKIs, activated HGF/c-Met signalling, a poor prognostic factor, may define a patient subset associated with longer survival by the tivantinib/erlotinib combination. TRIAL REGISTRATION NUMBER: NCT01580735. BMJ Publishing Group 2016-07-21 /pmc/articles/PMC5070235/ /pubmed/27843623 http://dx.doi.org/10.1136/esmoopen-2016-000063 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Original Research Azuma, Koichi Hirashima, Tomonori Yamamoto, Nobuyuki Okamoto, Isamu Takahashi, Toshiaki Nishio, Makoto Hirata, Taizo Kubota, Kaoru Kasahara, Kazuo Hida, Toyoaki Yoshioka, Hiroshige Nakanishi, Kaoru Akinaga, Shiro Nishio, Kazuto Mitsudomi, Tetsuya Nakagawa, Kazuhiko Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title_full | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title_fullStr | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title_full_unstemmed | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title_short | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib |
title_sort | phase ii study of erlotinib plus tivantinib (arq 197) in patients with locally advanced or metastatic egfr mutation-positive non-small-cell lung cancer just after progression on egfr-tki, gefitinib or erlotinib |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070235/ https://www.ncbi.nlm.nih.gov/pubmed/27843623 http://dx.doi.org/10.1136/esmoopen-2016-000063 |
work_keys_str_mv | AT azumakoichi phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT hirashimatomonori phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT yamamotonobuyuki phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT okamotoisamu phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT takahashitoshiaki phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT nishiomakoto phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT hiratataizo phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT kubotakaoru phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT kasaharakazuo phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT hidatoyoaki phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT yoshiokahiroshige phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT nakanishikaoru phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT akinagashiro phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT nishiokazuto phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT mitsudomitetsuya phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib AT nakagawakazuhiko phaseiistudyoferlotinibplustivantinibarq197inpatientswithlocallyadvancedormetastaticegfrmutationpositivenonsmallcelllungcancerjustafterprogressiononegfrtkigefitiniborerlotinib |